论文部分内容阅读
普鲁卡因酰胺对控制急性心律失常有效,但由于治疗范围狭窄和半衰期短,须每3～4小时给药,以致在长期门诊治疗中很不方便。而且,在许多病人,特别在缓慢乙酰化表型者中易发生红斑狼疮样综合征。N-乙酰普鲁卡因酰胺(Acecainide,NA-PA)是普鲁卡因酰胺的主要代谢产物,排出缓慢,甚至在肾功能正常时亦比普鲁卡因酰胺排出慢。在动物模型和人体具有抗心律失常作用,不产生抗核抗体,很少产生狼疮样综合征。其电生理作用和普鲁卡因酰胺有所不同。本文报道在23例慢性高度频发室性异位搏动病人中进行 NAPA 抗心律失常效
Procaine amide is effective in controlling acute arrhythmia, but due to the narrow therapeutic range and short half-life, it must be administered every 3 to 4 hours, rendering it inconvenient in long-term outpatient treatment. Moreover, lupus-like syndrome tends to develop in many patients, particularly in patients with slow acetylation phenotypes. Acetylcholine (NA-PA), the main metabolite of procainamide, is slowly excreted and is also discharged more slowly than procainamide even with normal renal function. In animal models and the human body has antiarrhythmic effects, does not produce antinuclear antibodies, rarely produce lupus-like syndrome. Its electrophysiological effects and procainamide vary. This article reports the 23 cases of chronic high frequency of ventricular ectopic beats in patients with NAPA anti-arrhythmic effect